COVID-19: Gastrointestinal manifestations, liver injury and recommendations

Creative Commons License

Özkurt Z., Tanriverdi E.

WORLD JOURNAL OF CLINICAL CASES, cilt.10, sa.4, ss.1140-1163, 2022 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 10 Sayı: 4
  • Basım Tarihi: 2022
  • Doi Numarası: 10.12998/wjcc.v10.i4.1140
  • Dergi Adı: WORLD JOURNAL OF CLINICAL CASES
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE
  • Sayfa Sayıları: ss.1140-1163
  • Anahtar Kelimeler: COVID-19, Gastrointestinal manifestations, Liver injury, Liver transplantation, SARS-CoV-2, SARS-COV-2, CORONAVIRUS, ACE2, INFECTION, GUT, TRANSMISSION, SYMPTOMS, RECEPTOR, PROTEIN
  • Atatürk Üniversitesi Adresli: Evet

Özet

Coronavirus disease 2019 (COVID-19) has caused a pandemic that affected all countries with nearly 270 million patients and 5 million deaths, as of as of December, 2021. The severe acute respiratory syndrome coronavirus 2 virus targets the receptor, angiotensin-converting enzyme 2, which is frequently found in human intestinal epithelial cells, bile duct epithelial cells, and liver cells, and all gastrointestinal system organs are affected by COVID-19 infection. The aim of this study is to review the gastrointestinal manifestations and liver damage of COVID-19 infection and investigate the severe COVID- 19 infection risk in patients that have chronic gastrointestinal disease, along with current treatment guidelines. A literature search was conducted on electronic databases of PubMed, Scopus, and Cochran Library, consisting of COVID- 19, liver injury, gastrointestinal system findings, and treatment. Liver and intestinal involvements are the most common manifestations. Diarrhea, anorexia, nausea/vomiting, abdominal pain are the most frequent symptoms seen in intestinal involvement. Mild hepatitis occurs with elevated levels of transaminases. Gastrointestinal involvement is associated with long hospital stay, severity of the disease, and intensive care unit necessity. Treatments and follow- up of patients with inflammatory bowel diseases, cirrhosis, hepatocellular carcinoma, or liver transplant have been negatively affected during the pandemic. Patients with cirrhosis, hepatocellular carcinoma, auto-immune diseases, or liver transplantation may have a greater risk for severe COVID-19. Diagnostic or therapeutic procedures should be restricted with specific conditions. Telemedicine should be used in non-urgent periodic patient follow up. COVID-19 treatment should not be delayed in patients at the risk group. COVID19 vaccination should be prioritized in this group.

Keywords: COVID-19; Gastrointestinal manifestations; Liver injury; Liver transplantation